Japanese breast cancer survival data reviewed for palbociclib combo

NCT ID NCT04735367

Completed Knowledge-focused Sponsor: Pfizer Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study in Japan reviewed medical records of 42 patients with HR+/HER2- advanced breast cancer who had been treated with palbociclib plus letrozole. The goal was to see how long patients lived after starting this treatment. It was a follow-up to an earlier phase 2 study and did not involve any new treatments or procedures.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: palbociclib plus letrozole
What this could lead to: If successful, this study could confirm the real-world survival benefit of this drug combination for Japanese patients with advanced breast cancer.
What could go wrong: This is a small, retrospective observational study with only 42 patients, so results may not apply to broader populations. It does not test a new treatment, only reviews past data.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm hormone receptor-positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

Aichi Cancer Center

Nagoya, 464-8681, Japan
Chiba cancer center

Chiba, Chiba, 260-8717, Japan
Hakuaikai Medical Corporation Sagara Hospital

Kagoshima, 892-0833, Japan
Hiroshima City Hiroshima Citizens Hospital

Hiroshima, Hiroshima, 730-8518, Japan
Kumamoto Shinto General Hospital

Kumamoto, 862-8655, Japan
Kumamoto University Hospital

Kumamoto, Kumamoto, 860-8556, Japan
Kyoto University Hospital

Kyoto, 606-8507, Japan
National Cancer Center Hospital

Chuo-ku, Tokyo, 104-0045, Japan
National Hospital Organization - Osaka National Hospital - Institute For Clinical Research

Osaka, 540-0006, Japan
National Hospital Organization Hokkaido Cancer Center

Sapporo, Hokkaido, 003-0804, Japan
National Hospital Organization Kyushu Cancer Center

Fukuoka, 811-1395, Japan
National Hospital Organization Shikoku Cancer Center

Matsuyama, Ehime, 791-0280, Japan
Saitama Cancer Center

Kita-adachi-gun, Saitama, 362-0806, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.